Serina Therapeutics (SER) Other Non-Current Assets (2017 - 2026)
Serina Therapeutics (SER) posted Other Non-Current Assets of $29000.0 for Q4 2025, up 20.83% sequentially from $24000.0 in Q3 2025.
Serina Therapeutics (SER) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Serina Therapeutics has reported Other Non-Current Assets for 9 years, with the latest figure at $29000.0 in Q4 2025.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $29000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29000.0 (changed N/A YoY) and the FY2025 annual result came in at $29000.0, changed N/A from the prior year.
- Other Non-Current Assets grew to $29000.0 in Q4 2025 per SER's latest filing, from $24000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $333000.0 in Q3 2024 and troughed at $24000.0 in Q3 2025.
- A 5-year average of $64750.0 and a median of $50000.0 in 2021 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets soared 566.0% in 2024, then sank 92.79% in 2025.
- Over 5 years, Other Non-Current Assets stood at $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then changed by 0.0% to $50000.0 in 2023, then jumped by 566.0% to $333000.0 in 2024, then sank by 91.29% to $29000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $29000.0, $24000.0, and $333000.0 for Q4 2025, Q3 2025, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 62.96 Mn |
| 10 | Serina Therapeutics | 43.44 Mn | 20.41 Mn | - | 25,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2024 | 333,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 50,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | 50,000.00 |
| Sep 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 50,000.00 |
| Jun 30, 2021 | 50,000.00 |
| Mar 31, 2021 | 50,000.00 |
| Dec 31, 2020 | 571,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |